

1 **Recent advances in efficacy of corticosteroids as adjunct therapy for**
2 **the treatment of community-acquired pneumonia in children: a**
3 **systematic review and meta-analysis.**

4
5 Lydia Mukanhaire^{1,2}, Junyan Wang², Xiaoyu Zong², Lingjian Zhang², Xiaohui
6 Zhou^{1#}, Jian Gong^{1,2#}

7 Affiliated Institutions:

8 1.School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University,
9 Nanjing 211198, P.R. China.

10 2.Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug
11 Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical
12 University, Shenyang 110016, P.R. China.

13

14 Authors email addresses:

15 Lydia Mukanhaire: lydiamukanhaire@gmail.com

16 Junyan Wang: 3032245115@qq.com

17 Xiaoyu Zong: 1277782939@qq.com

18 Lingjian Zhang: 564868976@qq.com

19

20 #Correspondence authors:

21 Xiaohui Zhou, zhxh@cpu.edu.cn

22 Jian Gong, gongjian_1979@163.com, ORCID: 0000-0002-4934-8599

23

24

25 **Abstract**

26 It has been recently shown that the adjunct use of corticosteroids in the treatment of
27 community-acquired pneumonia shorten the time taken to reach clinical stability (time
28 to clinical stability) in patients with community-acquired pneumonia (CAP).
29 Considering the hyperglycemic effects of corticosteroids, there are concerns about the
30 efficacy and safety of this therapy for children with CAP. Our objective is to evaluate
31 the influence of recent advances in adjunct corticosteroid use and/or aerosolized
32 antibiotic administration on admission to hospital with our main outcome being

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

33 duration of fever and hospital stay, and additional outcomes as the time to clinical
34 stability therapeutic efficacy, C-reactive protein and defervescence at 24, 48, and 72
35 hours after starting treatment in a well-defined cohort of children with community-
36 acquired pneumonia. Therapeutic efficacy is defined as the rate of achieving clinical
37 recovery with no fever, improvement or disappearance of cough, and improved or
38 normal laboratory values. Five academic literature databases will be searched using
39 Boolean keyword searches. Articles eligible for inclusion are those that present original
40 research with the study topic as CAP, the study was designed as a randomized
41 controlled trial (RCT) or clinical trial (CT) or an observational study with controls. The
42 review will result in a narrative synthesis that summarizes the effectiveness of
43 corticosteroid use in children.

44 Keywords: community-acquired pneumonia, corticosteroids, pediatrics, children,
45 efficacy

46

47 **Introduction**

48 **Rationale**

49 Pneumonia is an infection that inflames the air sacs in one or both lungs. The air sacs
50 may fill with fluid or pus, causing cough with phlegm or pus, fever, chills and difficulty
51 breathing. A variety of organisms, including bacteria, viruses and fungi can cause
52 pneumonia[1]. Pneumonia can range in seriousness from mild to life threatening[2]. It
53 is most serious for infants and young children, people older than 65, and people with
54 underlying health problems or weakened immune system[3]. Pneumonia can be broadly
55 categorized as community-acquired pneumonia, hospital acquired (nosocomial)
56 pneumonia and ventilator associated[4]. Specific pathogens such as mycoplasma
57 pneumoniae, streptococcus pneumoniae, respiratory syncytial virus and haemophilus
58 influenza type b have been found to increase the risk of hospitalization[5]. Risk factors
59 for pneumonia in children include infancy, premature birth, incomplete immunization,
60 maternal smoking or household tobacco smoke exposure, indoor air pollution, low
61 birthweight, malnutrition, lack of exclusive breastfeeding and overcrowding [6, 7].
62 Pneumonia can be spread in multiple ways, the viruses and bacteria that are found in a
63 child's nose or throat, can infect the lungs if they are inhaled[8]. They may also spread
64 via air-borne droplets from a cough or sneeze. Also, pneumonia may spread through
65 blood during and shortly after birth[9]. The presenting features of viral and bacterial
66 pneumonia are similar[10]. However, the symptoms of viral pneumonia may be more
67 numerous than bacterial pneumonia. In children under 5 years of age, who have cough
68 and/or difficult breathing, with or without fever, pneumonia is diagnosed by the
69 presence of either fast breathing or lower chest wall in-drawing where their chest moves
70 in or retracts during inhalation[11]. Wheezing is most common in viral infections.

71 Severely ill infants may be unable to feed or drink and may also experience
72 unconsciousness, hypothermia and convulsions[12]. Pneumonia is treated with
73 antibiotics, amoxicillin being the first line of treatment[13]. Hospitalization is required
74 for severe cases of pneumonia. The most effective way to prevent pneumonia is
75 immunization against Haemophilus Influenza type b (Hib), pneumococcus, measles
76 and whooping cough(pertussis)[14]. Adequate nutrition improves the child's natural
77 defenses, starting with exclusive breastfeeding for the first six months of life[15].
78 Encouraging good hygiene and providing affordable clean indoor stoves (in crowded
79 homes) helps to reduce pneumonia infection in children[16]. In children infected with
80 HIV are given cotrimoxazole daily to decrease the risk of contracting pneumonia[17].

81

82 **Community-acquired pneumonia**

83 Community-acquired pneumonia (CAP) is the most common type of pneumonia. It
84 occurs outside of hospitals and other healthcare facilities and may be caused by
85 respiratory syncytial virus, streptococcus pneumoniae being the most common bacterial
86 cause, bacteria like organisms like mycoplasma pneumoniae and fungi which comes in
87 soil and bird droppings[18] [19].

88

89 **Diagnosis of CAP**

90 **Clinical Diagnosis**

91 Tachypnoea, hypoxia, cough and increased work of breathing has been found to be
92 signs of pneumonia[20]. Common clinical symptoms of CAP include cough, fever,
93 chills, fatigue, dyspnea, rigors, and pleuritic chest pain. Depending on the pathogen, a
94 patient's cough may be persistent and dry, or it may produce sputum[21].The World
95 Health Organization criteria in the diagnosis of childhood pneumonia is categorized
96 as follows:

- 97 • In children < 2 months :> 60 breaths/minute
- 98 • In children 2-12 months:> 50 breaths/minute
- 99 • In children > 12 months :>40 breaths /minute

100

101 **Etiological diagnosis**

102 Virus infection, mostly by respiratory syncytial virus is more common in younger
103 children[22]. In older children, the most identified pathogen is streptococcus
104 pneumoniae, followed by mycoplasma and chlamydia[23]. Diagnostic modalities

105 available for etiological diagnosis include molecular diagnostics, microscopy, culture
106 and antigen detection[24]. Both bacterial and viral pneumonia exhibit a wide
107 distribution of acute phase reactants (blood count, C reactive protein, erythrocyte
108 sedimentation rate)[22].Upper respiratory tract secretions are useful in virological
109 diagnosis. Pulmonary TB should be considered in a child presenting with severe
110 pneumonia or pneumonia with a known TB contact[25].

111

112 **Radiological diagnosis**

113 The radiological signs of pneumonia overlap with those of collapse. Chest radiography
114 does not distinguish between viral and bacterial infection and is unable to detect early
115 changes in pneumonia.[7]However, chest radiography improves the diagnosis of
116 pediatric community acquired pneumonia to a certain degree and may prevent over-
117 treatment with antibiotics[26] .

118

119 **Assessment of severity**

120 The general appearance of a child should be assessed in order to evaluate the severity
121 of the illness. Any general danger sign requires a child to be referred to a
122 hospital[27].All children less than 2 months of age with signs of pneumonia require
123 hospital admission. Inability to drink/feed, vomiting everything, convulsions, lower
124 chest in-drawing, central cyanosis, lethargy, nasal flaring, grunting, head nodding, and
125 oxygen saturation <90% are predictors of death and can be used as indicators for
126 hospitalization[28].Pulse oximetry should also be performed in all children, using a
127 pediatric wrap-around probe. A saturation of<92% or 90% at higher altitudes (>1 800m)
128 indicates the need for hospital admission and supplemental oxygen[29]. Transfer to
129 pediatric intensive care unit should be considered when: the patient is shocked, failure
130 to maintain rising respiratory and pulse rates with clinical evidence of severe respiratory
131 distress, recurrent apnea or slow irregular breathing[30]

132

133 **Corticosteroid**

134 Corticosteroids are synthetic analogs of the natural steroid hormones produced by the
135 adrenal cortex and include glucocorticoids and mineral corticoids[31]. Corticosteroids
136 work primarily by modulating transcriptional, post-transcriptional, and post-
137 translational mechanisms within cellular nuclei to decrease the production of

138 inflammatory mediators[32]. Glucocorticoids are involved in metabolism and have
139 immune-suppressive, anti-inflammatory and vasoconstrictive effects while mineral
140 corticoids regulate electrolytes and water balance by affecting ion transport in the
141 epithelial cell of renal tubules[33]. Corticosteroids are readily absorbed in the
142 gastrointestinal tract and are highly protein-bound. They undergo hepatic metabolism
143 and renal excretion[31]. Corticosteroids at high concentrations will also inhibit the
144 production of B cells and T cells[34].

145

146 **How intervention might work**

147 With the increasing reported cases of pneumonia in recent years, there has been an
148 introduction of other supportive therapies for the treatment of MP infection[35].
149 Adjunct treatment therapies for CAP infections include the use of corticosteroids and
150 aerosolized antibiotics[36]. This might be due to the rapidly increased cases among
151 children, particularly sub-Saharan Africa and in East Asian countries such as Korea,
152 Japan, and China. As corticosteroids have been shown to be of use as adjunct therapy
153 in the treatment of community-acquired pneumonia (CAP) it is important to note their
154 effects and physiological roles. The clinical implications of these therapies have not
155 been fully elucidated[37], thus it is imperative to note any advancements in these
156 therapies. Moreover, there is need for supportive treatment options in CAP cases with
157 clinical deterioration. However, the use of corticosteroids in children is limited
158 because of their toxicity. Methylprednisolone may cause adverse effects such as
159 growth retardation, weight gain, Cushingoid features and osteoporosis in children[38,
160 39]. Therefore, they are contraindicated for premature infants. Aerosolized antibiotics
161 have been found to provide high concentration of drugs at the target site of action in
162 patients with pulmonary infections[17].

163

164 **Methods**

165 **Search strategy**

166 Our search strategy is developed based on systematic review best practices. To
167 identify relevant studies, we will perform an extensive search across 5 electronic full-
168 text databases; Medline/PubMed, Embase, the Cochrane Library, Scopus and Web of
169 Science with no language restrictions. These databases will be searched using
170 keywords for community acquired pneumonia, corticosteroid and children as shown
171 in a table (Table 2). Database specific Boolean search strategies were developed and
172 follow the general format: corticosteroid terms AND (community acquired
173 pneumonia terms or children's terms) we will search articles published from January

174 1967 to March, 2022 using a protocol designed for this study. The search terms used
175 for each database are listed below:

176 **Table 1. Databases included in the systematic review**

Databases	URL
Web of science	www.webofknowledge.com
Medline/PubMed	pubmed.ncbi.nlm.nih.gov/
Embase	www.embase.com
Scopus	www.elsevier.com
The Cochrane Library	www.cochranelibrary.com/
World Health Organization	www.who.int/health-topics/pneumonia

177

178 **Table 2. Search keywords**

Corticosteroid terms	Children terms
“Corticosteroids”	“Pediatrics”
“Prednisolone”	“Infant”
“Cortisone”	“Children”
“Hydrocortisone”	“Pre-school child”
“Budesonide”	“Child”
“Dexamethasone”	“Newborn”
“Prednisone”	“Toddler”
“Glucocorticoids”	“Kid”
“Mineral corticoids”	“Neonate”
Pneumonia terms	
“Community-acquired pneumonia”	
“Mycoplasma pneumonia”	
“Pediatric-pneumonia”	

“Childhood-pneumonia”	
-----------------------	--

179

180 **Study selection, quality assessment, and data extraction**

181 Studies are to be screened by two independent reviewers based on the title and
182 abstract, followed by full-text screening. The literature selection process will be
183 conducted in accordance with the Preferred Reporting Items for Systematic Reviews
184 and Meta-Analysis Protocols 2015 statement[40]. The quality of the selected studies
185 will be assessed using the Cochrane Risk of Bias Tools for RCTs and the revised Risk
186 of Bias Tool for Non-Randomized Studies for observational studies. The data
187 extraction form will include the following information: first author, year of
188 publication, population in each group, antibiotic treatment (macrolides/comparator),
189 patient characteristics (age and sex), and outcomes (durations of fever and
190 hospitalization, therapeutic efficacy, and defervescence rates at 24, 48, and 72 h after
191 starting treatment). Therapeutic efficacy is defined as the rate of achieving clinical
192 recovery with no fever, improvement or disappearance of cough, and improved or
193 normal laboratory values. Study selection, quality assessment, and data extraction to
194 be conducted. Any disagreements to be resolved through discussion. If the results of
195 the selected studies are unclear or missing, we will contact the corresponding study
196 investigators to obtain or confirm data

197

198 **Eligibility criteria**

199 Articles that meet the following inclusion criteria will be included: (1) the study topic
200 was CAP , defined as a disease showing no clinical or radiological improvement 48–
201 72 h after macrolide administration; (2) the subjects are children aged ≤ 12 years
202 (3)the study was designed as a randomized controlled trial (RCT) , Clinical Trial (CT)
203 or an observational study with controls; (4) the intervention agent should be a
204 corticosteroid known to be active against community-acquired pneumonia, such as
205 methylprednisolone (5) the control was a placebo; and (6) at least one of the
206 predetermined outcomes was reported. Animal and preclinical studies, as well as
207 articles other than original research articles (e.g., reviews, editorials, letters,
208 conference abstracts, and comments) are to be excluded. Studies with duplicate
209 subjects (i.e., different studies using the same outcome indicators in the same number
210 of patients) are also going to be excluded. Our search strategy will implement no
211 language restrictions, and non-English articles should be translated and included for
212 evaluation

213

214 **Data synthesis**

215 Statistical synthesis of data(meta-analyses) will be conducted. A systematic narrative
216 synthesis will be provided with the information presented in text and tables to
217 summarize and explain the characteristics and findings of the included studies.

218 The following is a tentative outline of how we will synthesize findings. First,
219 community-acquired pneumonia in children’s conceptualizations will be summarized.
220 This will include definitions provided by community-acquired pneumonia
221 researchers. Second, the antecedents of community-acquired pneumonia in children
222 will be summarized. This will likely to include the grouping of corticosteroid
223 therapies in the treatment of community-acquired pneumonia in children from
224 literature. Finally, the evidence on recent advances in efficacy of corticosteroids and
225 other supportive therapies in the treatment of community-acquired pneumonia will be
226 incorporated into the theoretical framework.

227

228 **Statistical analysis**

229 We will pool the findings from the included studies such as calculated mean, standard
230 deviation, and sample size. For outcomes presented as continuous variables, such as
231 fever duration, hospital stay length, and therapeutic efficacy, we will calculate mean
232 differences with 95% confidence intervals (CIs). For dichotomous outcomes such as
233 the achievement of defervescence after 24, 48, and 72 h of treatment, we will
234 calculate odds ratios (ORs) with 95%CIs. The average effect summary will be
235 calculated using a random-effects model (Mantel–Haenszel method) using Review
236 Manager 5.3 (The Cochrane Collaboration, London, UK) including the *I*² statistic. *I*²
237 of 25%, 50%, and 75% indicated low, moderate, and high heterogeneity, respectively.
238 To assess the risk of publication bias, we will use funnel plots for visual inspection;
239 Egger test flow chart of the selection process to be included in meta-analysis. The
240 strength of the body of evidence will be assessed using GRADE approach[41] .

241

242

243

244

245

246

247

248

249 **Flow chart of the selection process of studies to be included in the meta-analysis**

250

Identify records through database search

251

Identification



253

Remove duplicated records

254

255

Screening



Exclude records based on title only

256

257

Screen Records

258

Eligibility



Exclude records based on abstract review
1) Case report /series
2) Review or meta-analysis

260

261

262

Full-text articles assessed for eligibility

263

Included



Exclude records after full text review
1) No mention of community-acquired pneumonia
2) Inadequate study protocol (dependent, independent variables)
3) No relevant data provided

264

265

266

Include studies in meta-analysis

267 **Risk of publication bias**

268 The authors have no conflicts of interest. Ideally, additional reviewers would
269 participate in study screening and data extraction. However, this is not feasible since
270 this publication is not funded.

271

272 **Ethics and dissemination**

273 This systematic review protocol has been written following the PRISMA-P
274 guidelines and elaboration[40, 42].

275

276 **Discussion**

277 Corticosteroids may be imperative for the treatment of community-acquired
278 pneumonia. Therapeutic doses vary greatly, as do adverse effects. Patients require
279 education on what to expect with corticosteroid use, whether it be short course or
280 long-term use. Other pharmacological therapies may be necessary to counteract
281 corticosteroid-related adverse effects, such as gastric acid suppression, calcium and
282 vitamin D supplementation, and opportunistic infection prophylaxis. Providers must
283 weigh the risks versus benefits of corticosteroid use and utilize the lowest effective
284 dose for the least duration possible to avoid or minimize serious corticosteroid-
285 induced toxicities. This review searches for the efficacy of corticosteroids as adjunct
286 therapy in the treatment and management of community-acquired pneumonia in
287 children. There is an ongoing unclear elucidation on the effectiveness of
288 corticosteroids use specifically in children under the ages of 5. By carefully
289 examining the published literature to date, we will contribute a novel synthesis of
290 literature compared to “corticosteroid use in community-acquired pneumonia”
291 literature that has been published before.

292

293 **Supporting information**

294 1. Table .PRISMA-P checklist (Docx)

295 2. Search strategy draft(doc)

296 **Funding**

297 No funding was received for this study

298

299 **Author Contributions**

300 **Conceptualization:** Lydia Mukanhaire, Jian Gong

301 **Methodology:** Lydia Mukanhaire, Jian Gong

302 **Supervision:** Xiaohui Zhou, Jian Gong

303 **Writing-original draft:** Lydia Mukanhaire

304 **Writing-review & editing:** Junyan Wang, Xiaoyu Zong, Lingjian Zhang

305

306 **References**

307 1. Jain, V., et al., *Pneumonia Pathology*, in *StatPearls*. 2022, StatPearls Publishing

308 Copyright © 2022, StatPearls Publishing LLC.: Treasure Island (FL).

309 2. Stamm, D.R. and H.A. Stankewicz, *Atypical Bacterial Pneumonia*, in *StatPearls*. 2022,
310 StatPearls Publishing

311 Copyright © 2022, StatPearls Publishing LLC.: Treasure Island (FL).

312 3. Ferreira-Coimbra, J., C. Sarda, and J. Rello, *Burden of Community-Acquired Pneumonia and*
313 *Unmet Clinical Needs*. *Adv Ther*, 2020. **37**(4): p. 1302-1318.

314 4. Grassi, V. and G. Romanelli, *[Pneumonia: state-of-art and perspectives]*. *Recenti Prog Med*,
315 2006. **97**(12): p. 697-703.

316 5. Wang, Z., et al., *Investigation on Atypical Pathogens related with Community Acquired*
317 *Pneumonia and the Factors Associated with Mycoplasma Pneumoniae Infection in Jiangsu,*
318 *China*. *Clin Lab*, 2020. **66**(6).

319 6. Almirall, J., et al., *Risk Factors for Community-Acquired Pneumonia in Adults: A Systematic*
320 *Review of Observational Studies*. *Respiration*, 2017. **94**(3): p. 299-311.

321 7. Hassen, M., et al., *Radiologic Diagnosis and Hospitalization among Children with Severe*
322 *Community Acquired Pneumonia: A Prospective Cohort Study*. *Biomed Res Int*, 2019. **2019**: p.
323 6202405.

324 8. Alcón, A., N. Fàbregas, and A. Torres, *Pathophysiology of pneumonia*. *Clin Chest Med*, 2005.
325 **26**(1): p. 39-46.

326 9. Hooven, T.A. and R.A. Polin, *Pneumonia*. *Semin Fetal Neonatal Med*, 2017. **22**(4): p. 206-213.

327 10. March Mde, F. and C.C. Sant'Anna, *Signs and symptoms indicative of community-acquired*
328 *pneumonia in infants under six months*. *Braz J Infect Dis*, 2005. **9**(2): p. 150-5.

329 11. McCollum, E.D. and A.S. Ginsburg, *Outpatient Management of Children With World Health*
330 *Organization Chest Indrawing Pneumonia: Implementation Risks and Proposed Solutions*. *Clin*

- 331 Infect Dis, 2017. **65**(9): p. 1560-1564.
- 332 12. Dean, P. and T.A. Florin, *Factors Associated With Pneumonia Severity in Children: A*
333 *Systematic Review*. J Pediatric Infect Dis Soc, 2018. **7**(4): p. 323-334.
- 334 13. Bielicki, J.A., et al., *Effect of Amoxicillin Dose and Treatment Duration on the Need for*
335 *Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT*
336 *Randomized Clinical Trial*. Jama, 2021. **326**(17): p. 1713-1724.
- 337 14. Leung, D.T., M.J. Chisti, and A.T. Pavia, *Prevention and Control of Childhood Pneumonia and*
338 *Diarrhea*. Pediatr Clin North Am, 2016. **63**(1): p. 67-79.
- 339 15. Marangu, D. and H.J. Zar, *Childhood pneumonia in low-and-middle-income countries: An*
340 *update*. Paediatr Respir Rev, 2019. **32**: p. 3-9.
- 341 16. Accinelli, R.A., J.A. Leon-Abarca, and D. Gozal, *Ecological study on solid fuel use and*
342 *pneumonia in young children: A worldwide association*. Respirology, 2017. **22**(1): p. 149-156.
- 343 17. Zar, H.J. and S.A. Madhi, *Childhood pneumonia--progress and challenges*. S Afr Med J, 2006.
344 **96**(9 Pt 2): p. 890-900.
- 345 18. Lanks, C.W., A.I. Musani, and D.W. Hsia, *Community-acquired Pneumonia and Hospital-*
346 *acquired Pneumonia*. Med Clin North Am, 2019. **103**(3): p. 487-501.
- 347 19. Leung, A.K.C., A.H.C. Wong, and K.L. Hon, *Community-Acquired Pneumonia in Children*.
348 Recent Pat Inflamm Allergy Drug Discov, 2018. **12**(2): p. 136-144.
- 349 20. Shah, S.N., et al., *Does This Child Have Pneumonia?: The Rational Clinical Examination*
350 *Systematic Review*. Jama, 2017. **318**(5): p. 462-471.
- 351 21. Lutfiyya, M.N., et al., *Diagnosis and treatment of community-acquired pneumonia*. Am Fam
352 Physician, 2006. **73**(3): p. 442-50.
- 353 22. Claesson, B.A., et al., *Etiology of community-acquired pneumonia in children based on*
354 *antibody responses to bacterial and viral antigens*. Pediatr Infect Dis J, 1989. **8**(12): p. 856-62.
- 355 23. Nascimento-Carvalho, C.M., *Etiology of childhood community acquired pneumonia and its*
356 *implications for vaccination*. Braz J Infect Dis, 2001. **5**(2): p. 87-97.
- 357 24. Ning, G., et al., *The etiology of community-acquired pneumonia among children under 5 years*
358 *of age in mainland China, 2001-2015: A systematic review*. Hum Vaccin Immunother, 2017.
359 **13**(11): p. 2742-2750.
- 360 25. Nantongo, J.M., et al., *High incidence of pulmonary tuberculosis in children admitted with*
361 *severe pneumonia in Uganda*. BMC Pediatr, 2013. **13**: p. 16.
- 362 26. Soudack, M., et al., *The Added Value of the Lateral Chest Radiograph for Diagnosing*
363 *Community Acquired Pneumonia in the Pediatric Emergency Department*. Isr Med Assoc J,
364 2018. **20**(1): p. 5-8.
- 365 27. Ning, J., et al., *Valuable hematological indicators for the diagnosis and severity assessment of*
366 *Chinese children with community-acquired pneumonia: Prealbumin*. Medicine (Baltimore),
367 2016. **95**(47): p. e5452.
- 368 28. Nascimento-Carvalho, C.M., *Community-acquired pneumonia among children: the latest*
369 *evidence for an updated management*. J Pediatr (Rio J), 2020. **96 Suppl 1**: p. 29-38.
- 370 29. Ambroggio, L., et al., *Guideline Adoption for Community-Acquired Pneumonia in the*
371 *Outpatient Setting*. Pediatrics, 2018. **142**(4).
- 372 30. Shi, T., et al., *Risk factors for mortality from severe community-acquired pneumonia in*
373 *hospitalized children transferred to the pediatric intensive care unit*. Pediatr Neonatol, 2020.
374 **61**(6): p. 577-583.

- 375 31. Kapugi, M. and K. Cunningham, *Corticosteroids*. Orthop Nurs, 2019. **38**(5): p. 336-339.
- 376 32. Kaplan, D.J., et al., *The Simplified Science of Corticosteroids for Clinicians*. JBJS Rev, 2020.
- 377 **8**(11): p. e2000038.
- 378 33. Sibilia, J., [*Corticosteroids and inflammation*]. Rev Prat, 2003. **53**(5): p. 495-501.
- 379 34. Greaves, M.W., *Anti-inflammatory action of corticosteroids*. Postgrad Med J, 1976. **52**(612):
- 380 p. 631-3.
- 381 35. Wunderink, R.G. and L. Mandell, *Adjunctive therapy in community-acquired pneumonia*.
- 382 *Semin Respir Crit Care Med*, 2012. **33**(3): p. 311-8.
- 383 36. Huang, L., X. Gao, and M. Chen, *Early treatment with corticosteroids in patients with*
- 384 *Mycoplasma pneumoniae pneumonia: a randomized clinical trial*. J Trop Pediatr, 2014. **60**(5):
- 385 p. 338-42.
- 386 37. Wunderink, R.G., *Adjunctive therapy in community-acquired pneumonia*. *Semin Respir Crit*
- 387 *Care Med*, 2009. **30**(2): p. 146-53.
- 388 38. Aljebab, F., I. Choonara, and S. Conroy, *Systematic Review of the Toxicity of Long-Course Oral*
- 389 *Corticosteroids in Children*. PLoS One, 2017. **12**(1): p. e0170259.
- 390 39. Aljebab, F., I. Choonara, and S. Conroy, *Systematic review of the toxicity of short-course oral*
- 391 *corticosteroids in children*. Arch Dis Child, 2016. **101**(4): p. 365-70.
- 392 40. Moher, D., et al., *Preferred reporting items for systematic review and meta-analysis protocols*
- 393 *(PRISMA-P) 2015 statement*. Syst Rev, 2015. **4**(1): p. 1.
- 394 41. Schwingshackl, L., G. Rüschemeyer, and J.J. Meerpohl, [*How to interpret the certainty of*
- 395 *evidence based on GRADE (Grading of Recommendations, Assessment, Development and*
- 396 *Evaluation)*]. Urologe A, 2021. **60**(4): p. 444-454.
- 397 42. Shamseer, L., et al., *Preferred reporting items for systematic review and meta-analysis*
- 398 *protocols (PRISMA-P) 2015: elaboration and explanation*. Bmj, 2015. **350**: p. g7647.

399